Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
While this may very well drift lower from the pressure of continuous noteholder selling before they run out of their shares, I'm actually pretty amazed at the resilience and amount of buying picking up the shares in spite of the public PR that these shares most likely will be dumped into the market.
I see that as longer term positive news that there is someone(s) out there with much deeper pockets than I have buying into the conversion of noteholder shares.
Sam,
My reaction exactly when I first read the article. Good news that they are confident that expanding the parameters to more lesions will not negatively impact the phase 3 trial, but on the other hand, if enrollment was on a good pace for completion, there was not a need for the expansion.
So this PR and development might not be the price catalyst people will want it to be.
Note holders can only sell 50% the collective daily avg (currently 11.5MM) of their pro rata shares until the 15 day holding period. Not until 1/22 (the 15th trading day) can they sell above this restriction. They have access to 123MM aggregate.
Common sense says to me they put the petal to the metal today because they want another batch as fast as they can lay their hands on it which makes a fair amount of sense, why try to maximize profit margin on the first 15 million of 123 million
For those that read the filed documents regarding the "leak-out", is there any further clarification as to why we are seeing such large volume sales below .08?
Can they sell below .08 if the previous close was above .08 or are the converted shares not supposed to be sold period below .08?
Thanks
Nite briefly flashed over million shares on sell side at .065 a while back and now everyone is scattered between buying/selling in .06-.064 range.
Did Nite want to slow things down to pick up more shares at .06 or did he really want to unload a million shares.
Should know by end of day.
But really looking to next week when YE statements and balances are in the books and more people start looking at DCTH for the potential value in 2018 and 2019 going forward as a company out of debt, selling in Europe and Phase 3 progressing without change and with FDA approval.
Maybe he lives in Pennsylvania and is still shoveling out his driveway.
We wish MAXM a long holiday vacation.
Nice to see some healthy and steady buying on the ask this morning.
Interesting that we didn't get the weekly 8-K share update, but that could be either because of people on vacation for the holidays or they are very near completing their sales and will release final count soon.
Too many computers trading at the 10%-15% gain from yesterday. With MAXM sitting at 1.00, we could have a nice Santa rally today.
MAXM seems patiently parked at 1.00 this morning. Haven't watched the ticker all morning, but haven't seen it elsewhere. Maybe he was so aggressive yesterday in order to take his Christmas vacation starting today...
Merry Christmas to all.
Though green and red are both seasonal colors, I prefer green today.
I have no idea as to a precise number, but others on the board have given various analysis, with several thinking it's going to be in a range if current PPS doesn't go much lower to about 90M-130M total shares.
It's based on company's agreement with debt holders recently released in SEC filings.
I'm no expert, but from what others have expressed about the conversion shares, the rate and the action of MAXM this morning, it appears to me that MAXM may want to complete it share conversion before end of 2017 and is now not waiting as much for price to come to it as others keep going under him.
No idea how low he is willing to go, whether or not he has a price below which he won't go... but while we had several day of slow churn, MAXM seems a bit more aggressive to get rid of shares today.
Overall, I take that as an okay sign that he plans to complete conversion dumping by year end. Fro ST or DT, how to play that is your decision, for longer term outlook, the pain may be coming to a bearable ST end.
No need to make personal attacks here. It's a penny stock with unknowns and variables since there's always more going on behind the scenes than any one person might know.
The board is to let people express their opinions on the company and stock action with all others free to ignore, agree or disagree with. Let's leave personal attacks out of it.
It's good to hear contrary opinions and leave each to make their own conclusions.
Best to all.
Haven't been watching most of the day. See that MAXM is currently not listed on L2. Has MAXM continued to be on the sell most of the day?
Dmort,
Merry Christmas!
I don't frequent the board as in the past for a variety of reasons, but keep RGBP on watch list. Unfortunately, without revenue and with current outlook of no partnerships (in their own release) until several months down the line and the past 6 or so PRs all being variations of the same development, people who jump in and expect this to skyrocket, get tired and sell to move on to something else. Doesn't take much.
What I'm waiting for is the delayed or late 10-Q for end of September and what the current shares OS are and what they say about that. I anticipate it will be released over the Christmas holiday so as not to gain much attention.
If it states what I expect, I personally will be looking to buy back in near the .02s to .04s.
The science is there and developing, the management and how he handles things doesn't seem to be changing. Forging great deals that actually benefit shareholders is not his style.
I found it pitying that in a recent PR, he had to state they were filing patents for the benefit of shareholders. Wow, thanks!
Best to all who still have hope.
Board seems to have quieted as well as we await the next step. Silent anticipation.
At least they don't seem anxious about having to sell a specific Qty each day anymore. Maybe they hit an agreed Qty quota by certain date and now are just waiting for remainders to be completed.
Sitting at .0598 allows for a green close at least. Just nice that panic and forced selling pressure down has not been apparent. Whether and how long it lasts is anyone's guess, but the longer it stays away, the better our chances for this turning without a further leg down.
Every price point above $.054 reduces the OS by some multiple to under 100M, every price point below $.054 increases the OS by some multiple over 100M.
The one very good takeaway is that based on the current burn rate and price stabilization, DCTH is going to have an OS under 100M by the time this is all said and done, imo.
Will be interesting. I don't know how it's possible to estimate shares unloaded through MAXM since MAXM is often above the BID/ASK throughout the day, but I certainly hope you are right.
Rap, I don't know if anyone answered in private, but MAXM earlier was siting at .0515 without moving up or down much. Currently has moved up to and sitting at .079 along with PUMA.
Seems to be a slower, not rushed steadily working higher action on L2 with NITE and CDEL the main players on sell.
Beginning to look more promising. Quiet standoff as not as many people jumping under MAXM at .0515 to sell. Waiting to see how many shares MAXM has now at .0515 before moving.
Let's hope. If MAXM disappears should be a very good day for us.
Well, since the last 3 filings are about a week apart and it's been a week, there's a fairly good chance they will.
MAXM not in any hurry to move from .05. Others betting .05 holds and putting up quiet wall. Bids wanting price to come to them.
Pretty quiet standoff for now, but would love to see a break of .05 here.
Certainly no rush to sell at the moment.
"O Soave Fancuilla"
Well they first announced the intention on Sep 13th, then this headline on Sep 14th:
Delcath Announces Accelerated Listing on OTCQB
•September 14, 2017Comment
NEW YORK, Sept. 14, 2017-- Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that after conversations with both Nasdaq ..
Well it's pretty quiet at the moment and MAXM only at .375. Maybe MAXM has left for the day to beat the weekend traffic.
DCTH has already transitioned to QBPink, but would yesterdays FORM 25 posting with Dec 18th as official delisting date from NASDAQ have any influence on the timing of MAXM selling all the shares he needs?
In other words, we would expect MAXM to leave the sell side at least by next Friday?
Pretty solid fight over the .06-.0606 range.
Let's hope the base wins and pushes this higher.
Thanks for the info, but just to note, delisting doesn't occur until 10 days after the Form 25 date of 12/7/17.
Can you help me understand the OS count. After the RS, my brokerage shows only 1.4M shares OS, yet over 19M traded today.
Is this all DT or something else at play?
whoever sold lost more than they invested
Rgbp. .40 cents this year folks
While it is "good" news about development, it isn't new news as they keep explaining the same plan. Is very good that they haven't had any major scientific setbacks, but the timing of this news and recent articles may just be a preparation for the upcoming filing and the reality of how many shares have been and will be issued in order to continue the science.
Brace yourselves for the pricing of shares given out and see if the financials still so Koos' $50 loan.
I agree. Couldn't believe this has dropped so low so fast. Bought in yesterday at 2.18 and looking forward to the future price action. 2.18 after the 350 to 1 RS is only .0062 cents/share when it was trading at .03/share before the RS. Current pricing is a bargain in my opinion or can someone explain what has happened other than the RS to devalue DCTH from .03 to .0062 in just a couple days when the RS gives them access to more capital?
With I had more liquid to buy at current pricing.
Thank you very much for the detailed response. Didn't know we are still dealing with FDA approval here. Hopefully it's an easier and faster process than FDA approval for human drugs.
Jeremyan7,
I realize. It will all come down to the success of the science, how long it takes to get there and how the funds are raised between now and then. Koos has complete control to do whatever he wants and in that regard, who Koos is does and always will have an impact on the company, price of stock and future transaction in addition to the science.
In my mind, not much has changed from the stickered post of a year ago. The science may very well succeed - to what profit of investors is up for debate. Those with more than 1M shares may do very well.
If Koos had been issuing shares of RGBP at $1.00/share to raise funds as he recently did for Zander, we'd all be doing well I imagine, but he didn't and the stock price currently reflects that. How many shares he issues between now and any deal will directly impact the pricing, that's basically all I'm saying with Koos holding the key.
I will be interested in reading the upcoming 10-Q filing and seeing what has happened with volume of shares OS and at what price.
The fact that Zander was able to sell 900K shares at $1.00 each is intriguing as it is a vast change from the .01-.05 sales of shares for money going on at Regen.
I do not know anything about Veterinary issues. Can someone with knowledge post whether or not veterinary medicines are regulated, by whom and if so, how long to bring a treatment to approval?
Or, let's say, Zander discovers a cell treatment for arthritis in dogs, can they immediately sell it or does it have to be reviewed and get approval first from some entity?
Thanks
Thanks. You just made my point.
Looks like ENTB and Zander are much more valued than RGBP right now as Koos sold 900,000 Zander Shares for $1.00 each while he has been selling RGBP at .01-.03/share.
Jereyman7,
No stock investment can separate the product or service of the company from the company itself and its management.
Why do stocks shoot up or drop rapidly based on CEO hiring and firing? Not because the product has changed.
RGBP is no more a purely scientific play than was BMSN and regardless of how long you hold shares of BMSN or ENTB, you might not regain your initial investment.
RGBP owns the science and any deal with have to be a deal with Koos and company and the millions of shares and warrants they own, all of which impacts stock price because number of OS impacts valuation. Koos has issued almost 7,000,000,000 shares of BMSN. How many will he issue over the course of development of NR2F6? 1B, 2B, 3B? Less? What management does (promising to stop F&F shares after 6 months only to continue to issue shares for money at 80% discount) directly impacts the company, valuation, possibility of deals and therefore stock price.
To think that because the science succeeds, there will be a public auction of the science at highest value without any tie or impact of having to deal with Koos and his past is like having a theory that a film by Harry Weinstein today will draw a huge box office return just because it is a well produced film.
I hope your investment pays off. I've lost big time here in the past all while encouraging others to be patient because I believed management could change for the better. But I had to finally see the reality before me.
RGBP hired a firm at 10K/month to promote and seek partnerships. That company was an expert according to it's website for $1-5 million dollar deals, not $1-5B deals. To date other than the "we have been in conversations with big pharma" released in PRs for over 4 years now without any concrete funding, licensing or partnerships, we have no news of anything. There are still 2 people besides the hired firm employed to raise funds, but with all the progress and time passed, no news other than insider shares and funding at .01-.05/share when the stock then traded between .15-.20/share.
Now the recent PRs state that they "have decided" to not strike any partnerships until they have developed the science further and the recent scientific progress also has extended the timeframe previously given for establishing a strengthened candidate for small molecule testing.
We can only guess at what the real reasons are for these decisions, but the facts of the matter are that they don't have any influx of money other than selling more shares, they have a FDA approved pipeline product gathering dust on the shelves; they had other pipeline products being developed under contracts with prestigious doctors and institutions about which we have heard absolutely nothing for months; the 2 main scientists on which most of the pipeline products were based are no longer with the company... and the volume of interest in the stock has all but dried up, with a good day seeing less than $5,000 dollars in stock traded.
To go from where we are today to a projected Billion dollar deal is quite the dream. Lander's has basically told us that while they might release updates, the next step in the current development of NR2F6 product development is more than 5 months away without any other product development, interest or activity that we know of other than Koos continuing to spin companies, restructure internal shares and the like.
Given all of the above and the lessons I've learned losing a great portion of my investments here, I expect the stock price to drift further down before any hope of a sustained upward climb. When it drops to .02 or below, I may buy back some of the shares I've had to sell at great loss.
Great science, less than great management.